Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Inclusion Criteria:

- Verified medical history of overactive bladder for at least 6 months

- Capable of walking unassisted to use the bathroom

- Able to measure voided urine volume and complete the diary without assistance

- If the subject is currently being treated with an OAB medication, the subject is
willing to discontinue OAB medications while participating in this study

Exclusion Criteria:

- Diagnosis of a neurological disease affecting bladder function

- Stress incontinence, insensate incontinence, overflow incontinence or incontinence
due to urinary fistula

- History of incomplete bladder emptying, bladder outflow obstruction or post-void
residual bladder volume > 150 mL

- Males with benign prostatic hyperplasia or with a prostate-specific antigen (PSA) of
4 ng/mL or more

- Other urinary tract pathology such as malignancy, ureteric reflux, bladder stone,
uninvestigated hematuria, urethral stricture, or cystitis

- Prior treatment with intravesical or intraprostatic botulinum toxin in the last 2
years

- Myasthenia gravis

- Angle closure glaucoma

- Current implantation of interstim electrodes or vaginal surgical mesh

- Presence of a clinically significant medical condition at any time during the study

- Presence of clinically significant abnormalities in laboratory findings, physical
exam findings or vital signs

- Participated in an investigational drug trial within 3 months of screening